Levetiracetam for tardive dystonia: a case report

Mental state examination revealed anxiety/depressive features with speech difficulty. Levetiracetam acts on synaptic vesicle protein 2 (SV2); thereby inhibiting the release of various neurotransmitters and modulating glutamatergic, GABAergic, dopaminergic, and cholinergic systems.

Saved in:

Bibliographic Details
Published in:	Neurology India Vol. 62; no. 5; p. 559
Main Authors:	Mangot, Ajish, Trivedi, Satyakant, Kurrey, Ravindra, Dubey, Vaibhav
Format:	Journal Article
Language:	English
Published:	India Medknow Publications and Media Pvt. Ltd 01-09-2014 Medknow Publications & Media Pvt. Ltd
Subjects:	Anticonvulsants - therapeutic use Anxiety Case studies Dosage and administration Drug dosages Drug therapy Dystonia Female Humans Levetiracetam Medical treatment Middle Aged Movement Disorders - diagnosis Movement Disorders - drug therapy Panic attacks Piracetam - analogs & derivatives Piracetam - therapeutic use Treatment Outcome United States
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!